Like a rocky romance, Wall Street's love affair with AI stocks has hit a rough patch, but that doesn't mean the relationship ...

Headlines are crazy, but dividends stay true. This Valentine’s Day, it’s hard to name a more iconic duo than U.S. companies’ ...

Palantir has delivered remarkable returns in the past year and is trading at an expensive valuation, but there's room for more upside. The AI software-platform specialist is scratching the surface ...

While being the most expensive SaaS business in the market, there's a plausible narrative that Palantir may be fairly valued at a mere 30% revenue CAGR. Q4 2024 results give confidence to prior ...

Palantir Technologies (NASDAQ: PLTR) is probably the hottest stock on Wall Street. As of this writing, shares are up 51% year to date and more than 380% over the last 12 months. So, where will ...

I remain bullish on Palantir due to its strong revenue growth, operational success, and expanding moat, despite high valuation metrics. Risks include declining billings and reliance on interest ...

Palantir extended its streak of accelerating revenue growth. Commercial customers continue to embrace its AI platform. The stock's valuation is among the highest in the S&P 500. Palantir has ...

The booming demand for artificial intelligence (AI) software has supercharged Palantir Technologies (NASDAQ: PLTR) in the past year, with shares of the company rising more than 510%, as of this ...

Palantir Technologies (NASDAQ: PLTR) stock continued its rapid ascent after the data analytics and artificial intelligence (AI) software company reported strong fourth-quarter results that once ...

It's hard to believe that Palantir Technologies (NASDAQ: PLTR) traded for $6 per share in early 2023. Its share price recently shot past $100 after stellar Q4 earnings underlined the company's ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Palantir shares hit a new record last week after reporting a strong 2025 outlook and ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...